Review Article

An Updated List of Neuromedicinal Plants of Pakistan, Their Uses, and Phytochemistry

Table 5

The different phytochemicals effective in various neurological diseases and their current clinical phase status.

Sr #PhytochemicalsSourceFamilyDiseaseMechanismDevelopment stageTrade NameReference

1CannabidiolCannabis sativaCannabaceaeEpilepsyModulation of intracellular calcium and neuronal inhibitionFDA approved, 2018Epidiolex as 5- 10 mg/kg/day[189]

2CannabidolCannabis sativa L.CannabaceaeChronic Neuropathic painCB1 and CB2 receptor activationFDA approved, 2005Sativex Spray (CBD 25mg/ml + THC27mg/ml)[190]

3CapsaicinCapsicum annum L.SolanaceaePostherpetic neuralgiaTRPV1 activatorFDA approved, 2010Qutenza as Patch (179mg capsacin)[190]

4CurcuminCurcuma longaZingiberaceaeDementiaAnti-amyloid, AChEIphase II[191]

5GalantamineGalanthus nivalisAmaryllidaceaeAlzheimerAChEI, allosteric modulation of nicotinic ACh receptorFDA approved, 2004Razadyne as 8-12 mg BD[192]

6Huperzine AHuperzia serrataHuperziaceaeAlzheimerAChEI, inhibits NMDA and glutamate toxicityapproved in China[193]

7IbogaineTabernanthe ibogaApocynaceaeParkinsonDopaminergic agonist, NMDA antagonismpreclinical[193]

8PsychollatinePsychotria umbellateRubiaceaeParkinsonMAO inhibitorpreclinical[193]

9ResveratrolVitis vinifera L.VitaceaeAlzheimerReduces Aβ formation and promote Aβ decompositionphase II[194]

10Scyllo-InositolCornus florida L.CornaceaeAlzheimerBreakdown of neurotoxic fibrils, allowing amyloid peptides to clear the body rather than form amyloid plaquesphase II[195]

FDA: food and drug administration; TRPV1: transient receptor potential vanilloid 1; CB1 and CB2: cannabinoid receptor type 1 & type 2; Ach: acetylcholine; AChEI: acetylcholinesterase inhibitor; CBD: cannabidiol; THC: tetrahydrocannabinol; BD: bis in die; NMDA: N-methyl-D-aspartate; MAO: monoamine oxidase; Aβ: amyloid beta.